LTR Pharma has today released its Half Year Financial Report for the period ended 31 December 2023.
This has been a defining period for the Company, marked by a successful ASX debut on 11 December 2023, and rapid progress towards our pivotal bioequivalence study.
Key highlights include:
- Successfully completed an oversubscribed IPO. The Company listed on the ASX on 11 December 2023 and raised $7M
- Presented SPONTAN intranasal spray clinical data to a global audience at the World Meeting on Sexual Medicine in Dubai
- Key scientific and clinical adviser Professor Eric Chung honoured with the prestigious ISSN Tanagho Prize at the World Meeting on Sexual Medicine for the most innovative research
- Completion of key milestones for its upcoming bioequivalence study, including commercial packaging studies and commencement of patient recruitment